Thrombosis in conversation

Can real-world evidence improve treatment selection and individualised care for AF in stroke prevention? Dr Proietti and Professor Lip discuss.

“Wearable technologies for stroke prevention are an exciting trend in the field” Dr Proietti and Professor Lip examine the benefits and disadvantages of wearable technologies for AF screening and detection in stroke prevention.

Dr Rajasekhar and Dr Barnes consider treatment selection for CAT, highlighting the role of warfarin, and discuss optimal treatment length and the use of IVC filters according to current guidelines.

“Why did a patient get their blood clot in the first place, and how does that influence our decisions?” Dr Barnes is joined by Dr Anita Rajasekhar for a discussion of the causes and risk factors of VTE in people without cancer, and the relationship of risk and cause with treatment selection. With reference to clinical guidance, Dr Rajasekhar talks about diagnosis of recurrent VTE in the clinical s...

Dr Deborah Siegal and Dr Barnes discuss thrombocytopenia and its treatment, including anticoagulation therapy and the inferior vena cava (IVC) filter, and touch on the challenge of balancing bleeding risk with VTE recurrence in people with brain tumours.

“How do we apply [clinical trial data] to patients we see every day in clinic?” Dr Gregory Piazza and Dr Barnes analyse real-world VTE data, highlighting shared decision-making for determining the most suitable anticoagulation therapy for a person with VTE.

“If there is a compliance and an adherence issue, it’s with the injectables” Dr Alok Khorana joins Dr Barnes to discuss the real-world versus clinical trial evidence of adherence to injectables, including the importance of taking a patient’s values and preferences into account when making treatment decisions.

Dr Alok Khorana and Dr Barnes examine why cancer can drive higher risk of VTE and the importance of warning patients about the symptoms of a blood clot.